Atezolizumab

Atezolizumab plus bevacizumab conferred the longest OS seen in a phase 3 study for treatment-naive advanced hepatocellular carcinoma, according to updated results of the IMbrave150 study presented at Gastrointestinal Cancers Symposium.

2020 presented many challenges, including the transformation of conferences and meetings into virtual events.

The FDA granted breakthrough therapy designation to tiragolumab combined with atezolizumab for the first-line treatment of patients with metastatic non-small cell lung cancer.

This year has seen some groundbreaking advances in genitourinary oncology, particularly in the fields of prostate, kidney and urothelial cancers.

The overprescribing and overuse of antibiotics has been scrutinized in recent years due to the threat of antimicrobial resistance.

The addition of atezolizumab to neoadjuvant chemotherapy improved pathologic complete response rates regardless of PD-L1 expression in early triple-negative breast cancer, according to data presented at ESMO Virtual Congress 2020.

The addition of atezolizumab to paclitaxel failed to significantly prolong PFS for patients with PD-L1-positive metastatic triple-negative breast cancer, according to phase 3 study results presented during ESMO Virtual Congress 2020.

The FDA alerted health care professionals and oncology researchers that a trial of atezolizumab plus paclitaxel did not appear effective for the treatment of patients with advanced triple-negative breast cancer.

National Prostate Cancer Awareness Month is observed every September.

The FDA today approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600-positive advanced melanoma, according to a manufacturer-issued press release.